Please assess the completion status of the following clinical trial:

Trial Title: Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must have been previously treated CLL/SLL~* Must have CD20 expression~* ECOG PS =\<3~* No prior Campath-1H~* No active infection requiring antibiotics~* No concurrent immunosuppressive therapy~* No prior history demyelinating neurologic disease~* No active viral hepatitis~Exclusion Criteria:~* No pregnant or breastfeeding women~* ECOG PS =4~* Life expectancy of \>12 weeks~* Patients with bilirubin or creatinine\>3.0 mg/dl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Etanercept 25 mg administered sub-cutaneously twice weekly (Monday and Thursday) weeks 1-5 of therapy (total of 10 doses). The third dose of etanercept will be administered 1 hour prior to receiving rituximab. Rituximab: Patients will receive 375 mg/M2 of rituximab three times weekly for four weeks (a total of 12 doses of rituximab).

Based on this trial design, predict the completion outcome and termination type (if applicable).